BRPI0412007A - mutagênese look-through - Google Patents

mutagênese look-through

Info

Publication number
BRPI0412007A
BRPI0412007A BRPI0412007-8A BRPI0412007A BRPI0412007A BR PI0412007 A BRPI0412007 A BR PI0412007A BR PI0412007 A BRPI0412007 A BR PI0412007A BR PI0412007 A BRPI0412007 A BR PI0412007A
Authority
BR
Brazil
Prior art keywords
libraries
amino acids
function
mutagenesis
look
Prior art date
Application number
BRPI0412007-8A
Other languages
English (en)
Inventor
Roberto Crea
Original Assignee
Bioren Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioren Inc filed Critical Bioren Inc
Publication of BRPI0412007A publication Critical patent/BRPI0412007A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"MUTAGêNESE LOOK-THROUGH". Um método de mutagênese através do qual um aminoácido predeterminado é introduzido em cada e qualquer posição de um conjunto selecionado de posições numa região pré-selecionada (ou diversas regiões diferentes) de um polipeptídio para produzir uma biblioteca de análogos polipeptídicos. O método é baseado na premissa que determinados aminoácidos desempenham um papel crucial na estrutura e função de proteínas. Podem ser geradas bibliotecas que contêm apenas análogos polipeptídicos desejados e que são de tamanho razoável para pesquisa. As bibliotecas podem ser utilizadas para estudar o papel de aminoácidos específicos na estrutura e função de polipeptídios e para desenvolver polipeptídios novos ou melhorados, tais como anticorpos, fragmentos de anticorpos, anticorpos de cadeia única, enzimas e ligantes.
BRPI0412007-8A 2003-06-27 2004-06-25 mutagênese look-through BRPI0412007A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48328203P 2003-06-27 2003-06-27
PCT/US2004/020306 WO2005003345A2 (en) 2003-06-27 2004-06-25 Look-through mutagenesis

Publications (1)

Publication Number Publication Date
BRPI0412007A true BRPI0412007A (pt) 2006-08-15

Family

ID=33563915

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412007-8A BRPI0412007A (pt) 2003-06-27 2004-06-25 mutagênese look-through

Country Status (14)

Country Link
US (1) US20050136428A1 (pt)
EP (1) EP1660655B1 (pt)
JP (2) JP4791960B2 (pt)
KR (1) KR20060034650A (pt)
CN (1) CN1836041A (pt)
AU (1) AU2004254352A1 (pt)
BR (1) BRPI0412007A (pt)
CA (1) CA2542192C (pt)
ES (1) ES2609102T3 (pt)
IL (1) IL172736A0 (pt)
NO (1) NO20060108L (pt)
RU (1) RU2005140664A (pt)
WO (1) WO2005003345A2 (pt)
ZA (1) ZA200510460B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
JP5143551B2 (ja) 2004-07-06 2013-02-13 バイオレン，インク． ユニバーサル抗体のライブラリー
ATE528396T1 (de) 2004-07-06 2011-10-15 Bioren Inc Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften
WO2006014477A1 (en) * 2004-07-06 2006-02-09 Bioren, Inc. HIGH AFFINITY ANTI-TNF-α ANTIBODIES AND METHOD
US20080207467A1 (en) * 2005-03-03 2008-08-28 Xencor, Inc. Methods for the design of libraries of protein variants
US20060234303A1 (en) * 2005-03-03 2006-10-19 Xencor, Inc. Methods for the design of libraries of protein variants
EP1877441A2 (en) * 2005-04-26 2008-01-16 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
RU2008110060A (ru) * 2005-08-15 2009-09-27 Арана Терапьютикс Лимитед (Au) Сконструированные антитела с каркасными участками приматов нового света
US8716195B2 (en) * 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
WO2007086994A1 (en) * 2005-11-15 2007-08-02 Balyasnikova Irina V Single chain fragment of monoclonal antibody 9b9 and uses thereof
US7981414B2 (en) 2005-12-20 2011-07-19 Cephalon Australia Pty Ltd Anti-inflammatory dAb
EP1987064A4 (en) 2006-02-01 2010-04-07 Arana Therapeutics Ltd DOMAIN ANTIBODY CONSTRUCT
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
WO2007112054A2 (en) * 2006-03-23 2007-10-04 Sea Lane Biotechnologies, Llc Facilitation of translocation of molecules through the gastrointestinal tract
WO2007134327A2 (en) 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
WO2007136840A2 (en) * 2006-05-20 2007-11-29 Codon Devices, Inc. Nucleic acid library design and assembly
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CN101548034B (zh) * 2006-10-02 2013-11-13 航道生物技术有限责任公司 多样性合成肽和多肽文库的设计和构建
EP2078077A2 (en) * 2006-10-04 2009-07-15 Codon Devices, Inc Nucleic acid libraries and their design and assembly
BRPI0812446A2 (pt) * 2007-06-06 2014-10-14 Danisco Us Inc Genecor Division Métodos para aperfeiçoamento de propriedades de proteína múltiplas
WO2009009045A2 (en) * 2007-07-10 2009-01-15 The Scripps Research Institute Escape libraries of target polypeptides
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
EP2222846B1 (en) * 2007-08-10 2017-05-03 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
WO2009121004A2 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
EP2131243B1 (en) * 2008-06-02 2015-07-01 ASML Netherlands B.V. Lithographic apparatus and method for calibrating a stage position
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
AU2010233658B2 (en) 2009-04-10 2013-11-28 Ablynx Nv Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
EP2438087B1 (en) 2009-06-05 2017-05-10 Ablynx N.V. Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
KR20210013294A (ko) 2009-07-17 2021-02-03 바이오아트라, 엘엘씨 생산 숙주에서 항체/단백질 성능과 발현을 동시에 통합 선택하고 진화시키는 방법
GB0914691D0 (en) * 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
EP3434769B1 (en) 2009-10-30 2020-11-25 Novartis AG Universal fibronectin type iii bottom-side binding domain libraries
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
CA2805862A1 (en) 2010-07-30 2012-02-02 Novartis Ag Fibronectin cradle molecules and libraries thereof
US9753040B2 (en) 2010-12-01 2017-09-05 Mitsubishi Tanabe Pharma Corporation Polynucleotide construct capable of displaying fab in a cell-free translation system, and method for manufacturing and screening fab using same
US10138302B2 (en) 2011-09-23 2018-11-27 Ablynx N.V. Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
EP2820043B1 (en) 2012-03-02 2020-01-15 Ablynx N.V. Biparatopic pseudomonas aeruginosa pcrv binding single variable domain antibodies
US9777055B2 (en) 2012-04-20 2017-10-03 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
TR201910420T4 (tr) * 2012-05-25 2019-08-21 Chr Hansen As Geliştirilmiş süt pıhtılaştırma niteliklerine sahip kimozin varyantları.
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
KR101600902B1 (ko) 2012-12-11 2016-03-10 주식회사 셀레믹스 코돈 조합화 및 변이유발을 이용한 유전자 라이브러리의 합성 방법
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
CA2924520C (en) * 2013-11-01 2023-09-26 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
CN104805507B (zh) * 2014-01-29 2019-01-22 杭州康万达医药科技有限公司 噬菌体展示文库及其应用和制备方法
US10982204B2 (en) 2014-02-26 2021-04-20 Chr. Hansen A/S Variants of chymosin with improved milk-clotting properties
CA2963712A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
EP3310914B1 (en) 2015-06-22 2022-04-06 Chr. Hansen A/S Variants of chymosin with improved properties
CA2995755A1 (en) 2015-08-31 2017-03-09 Chr. Hansen A/S Variants of chymosin with improved properties
US11484592B2 (en) * 2016-01-08 2022-11-01 Momotaro-Gene Inc. Combination therapy using REIC/Dkk-3 gene and a checkpoint inhibitor
WO2017198829A1 (en) 2016-05-19 2017-11-23 Chr. Hansen A/S Variants of chymosin with improved milk-clotting properties
US10954505B2 (en) 2016-05-19 2021-03-23 Chr. Hansen A/S Variants of chymosin with improved milk-clotting properties
CN109843922B (zh) 2016-09-02 2023-10-03 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
KR102847676B1 (ko) 2017-12-15 2025-08-21 알레타 바이오쎄라퓨틱스, 인크. Cd19 변이체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0527809B1 (en) * 1990-04-05 1995-08-16 CREA, Roberto Walk-through mutagenesis
WO1995023813A1 (en) * 1994-03-04 1995-09-08 Merck & Co., Inc. In vitro antibody affinity maturation using alanine scanning mutagenesis
WO2001044463A1 (en) * 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes

Also Published As

Publication number Publication date
EP1660655A2 (en) 2006-05-31
CA2542192A1 (en) 2005-01-13
JP2011182794A (ja) 2011-09-22
RU2005140664A (ru) 2007-08-27
NO20060108L (no) 2006-03-24
CN1836041A (zh) 2006-09-20
KR20060034650A (ko) 2006-04-24
EP1660655B1 (en) 2016-11-02
ES2609102T3 (es) 2017-04-18
JP4791960B2 (ja) 2011-10-12
ZA200510460B (en) 2006-11-29
JP2007524390A (ja) 2007-08-30
CA2542192C (en) 2013-05-28
AU2004254352A1 (en) 2005-01-13
IL172736A0 (en) 2006-04-10
WO2005003345A3 (en) 2005-03-24
US20050136428A1 (en) 2005-06-23
JP5358604B2 (ja) 2013-12-04
WO2005003345A2 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
BRPI0412007A (pt) mutagênese look-through
ES2078518T3 (es) Mutagenesis por desplazamiento completo.
EP1774019A4 (en) LOOK-THROUGH MUTAGENESIS FOR THE DEVELOPMENT OF CHANGED POLYPEPTIDES WITH IMPROVED PROPERTIES
Creighton Intermediates in the refolding of reduced ribonuclease A
NO963371L (no) Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det
Kuznetsov et al. Isolation of a 45-kDa fragment from the kinesin heavy chain with enhanced ATPase and microtubule-binding activities
Hirschman et al. Protein-polysaccharide loss during endochondral ossification: immunochemical evidence
Fullmer et al. Bovine intestinal calcium-binding proteins: Purification and some properties
DE69837095D1 (de) Fluorierung von proteinen und peptiden für positronemissionstomographie
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
WO2002042427A3 (en) Mass tags for quantitative analysis
DK0770876T3 (da) En screening-fremgangsmåde til at identificere ligander for målproteiner
Pasquini et al. Effects of plasmin on human factor VIII (AHF)
DE60215498D1 (de) Verfahren zur bestimmung von polypeptiden
ES2079621T3 (es) Procedimiento de identificacion o de titulacion de proteinas y aplicaciones.
DK0496725T3 (da) Kompleks indeholdende koagulationsfaktor IX
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
Edgington et al. Conformational and structural modulation of the NH2-terminal regions of fibrinogen and fibrin associated with plasmin cleavage.
DE3775389D1 (de) Verwendung von interleukin-1-proteinen gegen arthritis.
BRPI0406265A (pt) Método para análise eletroforética capilar, métodos para pesquisa e tipagem de proteìnas monoclonais, processo para preparação de anticorpos modificados, anticorpos modificados, kit para detecção e tipagem de proteìnas monoclonais e uso de anticorpos
DE50105263D1 (de) Verfahren zur analyse von proteinen
DE69409237D1 (de) Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten
Subramanian et al. Characterization of a mutant form of ribosomal protein S1 from Escherichia coli.
CA2019872A1 (en) Method and kit for determining the functional activity of protein s in human plasma
BR9910725A (pt) Indução de proteìnas e peptìdeos antibióticos por proteìnas lait/s cd14

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.